[Drug-eluting stents in complex lesions].
Interventional cardiology has evolved tremendously over the past two years with the advent of drug-eluting stents. The RAVEL trial was the first randomized study conducted with sirolimus-eluting stents in a selected population of patients in whom a 0% rate of binary restenosis was achieved. The objective of the SIRIUS trial conducted in a more complex patient population was to test the efficacy of the sirolimus-eluting stent in high-risk settings such as coronary bifurcation lesions.